Blog
RSS FeedPosted by Michael Wonder on 20 May 2021
Patients with rare blood disorders to receive new treatment option, says NICE
20 May 2021 - Hundreds of people with two rare blood disorders will soon have access to a new treatment regimen ...
Posted by Michael Wonder on 19 May 2021
Pfizer withdraws evidence submission for Staquis
19 May 2021 - NICE is unable to make a recommendation on the use of crisaborole for the treatment of people ...
Posted by Michael Wonder on 19 May 2021
NICE terminates yet another appraisal of a cancer medicine
19 May 2021 - This time it is for a new medicine for patients with multiple myeloma. ...
Posted by Michael Wonder on 18 May 2021
Northern Ireland faces ‘huge’ rise in generic medicine prices
18 May 2021 - Large increase likely after end of Brexit grace period, warns UUP head Simon Aiken. ...
Posted by Michael Wonder on 17 May 2021
Optimising managed access: lessons from the Cancer Drugs Fund
14 May 2021 - The desire, opportunity, and willingness to increase access to potentially life saving cancer treatments has mounted in ...
Posted by Michael Wonder on 14 May 2021
NICE says final ‘no’ to BMS’ Zeposia for multiple sclerosis
14 May 2021 - NICE has issued a final “no” to Bristol-Myers Squibb’s oral MS drug Zeposia (ozanimod), in a ...
Posted by Michael Wonder on 14 May 2021
Colorectal cancer patients with rare mutations to benefit from life-extending treatment
14 May 2021 - NICE recommends pembrolizumab for colorectal cancer patients with rare mutations. ...
Posted by Michael Wonder on 12 May 2021
NICE rejects Pfizer’s rare heart disease treatment Vyndaqel
12 May 2021 - Pfizer’s Vyndaqel has been rejected by NICE as a treatment for the rare heart condition transthyretin ...
Posted by Michael Wonder on 06 May 2021
Preliminary NICE 'no' for Merck's Bavencio
6 May 2021 - NICE has issued a preliminary rejection of NHS funds for use of Merck Serono's Bavencio (avelumab) ...
Posted by Michael Wonder on 28 Apr 2021
Thousands with high cholesterol set to benefit from new treatment on the NHS
28 April 2021 - Thousands of people with high cholesterol will soon have access to a new treatment option on the ...
Posted by Michael Wonder on 22 Apr 2021
The thorny issue of value alignment: how development-focused health technology assessment can help find win–win situations for patients and health care systems and commercial investors
20 April 2021 - We agree that there is always likely to be some tension between commercial interests and maximising societal ...
Posted by Michael Wonder on 22 Apr 2021
NICE recommends new treatment for rare blood disorder
22 April 2021 - Hundreds of people with a rare blood disorder have access to a new treatment regimen following draft ...
Posted by Michael Wonder on 22 Apr 2021
Delcath Systems announces revised NICE guidance for Chemosat in the United Kingdom
21 April 2021 - Recommends special arrangement designation which increases reimbursement options. ...
Posted by Michael Wonder on 21 Apr 2021
Novartis’ MS therapy Kesimpta wins NICE backing
21 April 2021 - Novartis’ Kesimpta has been recommended by NICE for the treatment of relapsing-remitting multiple sclerosis in adult ...
Posted by Michael Wonder on 21 Apr 2021
Chemotherapy-free treatment option to be offered to patients with England’s most common leukaemia
20 April 2021 - Acalabrutinib, taken as a twice daily tablet, is recommended as an option for adults with untreated ...